Dengue fever Brazilian vaccine approved by the end of 2024?
Market Rules
Dengue fever is a disease caused by a virus transmitted by Aedes aegypti mosquitoes. Its severe symptoms can evolve to hemorrhagic fever, and lead to complications that include the Guillain-Barré Syndrome.
There is no specific drug to kill the virus, and the treatment is based on symptoms management only. For that reason, an effective vaccine against the Dengue virus is long needed.
The Brazilian Butantan Institute is working on a fully national vaccine, designed to prevent infection from all 4 types of the virus. Phase three clinical trials of the vaccine are underway. Currently, the last volunteers included in the tests are being monitored, which means that the process of developing the immunizing agent is in its final phase. The survey is expected to be completed by 2024. After that, the vaccine would need sanitary approval from ANVISA (Brazil's health regulation agency) to be distributed by the Public Health System (SUS).
If ANVISA approves the Dengue fever vaccine by December 2024, this market will resolve to "Yes".